Acquired Long QT Syndrome

A. John Camm, MD, FRCP, FESC, FACCProfessor of Clinical Cardiology and Head, Department of Cardiological Sciences, St. George’s Hospital Medical School, London Marek Malik, PhD, MD, DSc, FACC, FECSProfessor of Cardiac Electrophysiology, Department of Cardiological Sciences, St. George’s Hospital Medical School, LondonYee Guan Yap, BMedSci, MBBS, MRCPBritish Heart Foundation Research Fellow in Cardiology, Department of Cardiological Sciences, St. George’s Hospital Medical School, London

• Preface vi1 Introduction 12 Mechanisms of acquired QT prolongation and torsades de pointes 83 Measurement of the QT interval and repolarization assessment 244 Introduction to drug-induced long QT syndrome 605 Risk of QT prolongation and torsades de pointes with antiarrhythmic drugs 696 Risk of QT prolongation and torsades de pointes with antihistamines 877 Risk of QT prolongation and torsades de pointes with psychotropic drugs 1028 Risk of QT prolongation and torsades de pointes with antimicrobial and antimalarial drugs 1219 Risk of QT prolongation and torsades de pointes with prokinetics and miscellaneous other drugs 14010 Acquired long QT syndrome secondary to cardiac conditions 16311 Acquired long QT syndrome secondary to noncardiac conditions 17112 Perspective on drug-induced repolarization changes 182Index 191